Valuation: Cerevel Therapeutics Holdings, Inc.

Market Cap 8.19B 7.17B 6.61B 6.13B 11.65B 781B 11.8B 79.1B 30.78B 384B 30.76B 30.09B 1,330B P/E 2022
-13.6x
P/E 2023 -15.9x
Enterprise Value 7.5B 6.57B 6.05B 5.61B 10.66B 715B 10.8B 72.38B 28.17B 351B 28.15B 27.53B 1,217B EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
93.64%
Yield 2022 *
-
Yield 2023 -
3 years 19.59
Extreme 19.59
44.99
5 years 19.59
Extreme 19.59
46.16
10 years 9
Extreme 9
46.16
Manager TitleAgeSince
President 59 2024-07-31
Chief Tech/Sci/R&D Officer 57 2019-04-30
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 2021-01-19
Director/Board Member 59 2024-07-31
Date Insider Type Main position Quantity % Market Cap.
24-07-31Issuer sale

Director

93,932 0.0516%
24-07-31Issuer sale

Head of Human Resources

800,774 0.4395%
24-07-31Issuer sale

Director

151,795 0.0833%
Change 5-day change 1-year change 3-year change Capi.($)
+0.74%-.--%-.--%+42.28% 8.19B
-0.34%-0.15%+73.90%+132.68% 57.73B
-0.93%-2.54%+73.64%+93.71% 54.69B
-3.71%-0.35%-14.61%-11.19% 23.75B
-0.05%+6.49%+14.05%+451.36% 24.18B
-2.70%+6.30%+46.83%-2.70% 19.82B
+2.37%+4.09%+42.85%-27.32% 17.14B
+3.58%+13.78%+196.41%+348.55% 16.75B
-1.81%+17.84%+45.86% - 15.57B
-0.57%+2.30%+20.33%+187.27% 13.96B
Average -0.34%+5.22%+49.92%+134.96% 25.18B
Weighted average by Cap. -0.57%+4.02%+56.54%+134.24%

Financials

2022 2023
Net sales - -
Net income -352M -308M -284M -263M -500M -33.53B -507M -3.39B -1.32B -16.46B -1.32B -1.29B -57.06B -433M -379M -349M -324M -615M -41.29B -624M -4.18B -1.63B -20.27B -1.63B -1.59B -70.27B
Net Debt -523M -458M -422M -392M -744M -49.91B -754M -5.05B -1.97B -24.5B -1.96B -1.92B -84.94B -695M -609M -561M -521M -989M -66.33B -1B -6.71B -2.61B -32.56B -2.61B -2.55B -113B
Logo Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Employees
355
  1. Stock Market
  2. Stocks
  3. CERE Stock